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 ActVB is the NADH:flavin oxidoreductase participating in the last step 
of actinorhodin synthesis in Streptomyces coelicolor. It is the prototype of a 
whole class of flavin reductases with both sequence and functional similarities. 
The mechanism of reduction of free flavins by ActVB has been studied. 
Although ActVB was isolated with FMN bound, we have demonstrated that it is 
not a flavoprotein. Instead ActVB contains only one flavin binding site, suitable 
for the flavin reductase activity and with a high affinity for FMN. In addition, 
ActVB proceeds by an ordered sequential mechanism, where NADH is the first 
substrate. Whereas ActVB is highly specific for NADH, it is able to catalyze 
the reduction of a great variety of natural and synthetic flavins, but with Km 
values ranging from 1 (FMN) to 69 (lumiflavin) M. We show that both the 
ribitol-phosphate chain and the isoalloxazine ring contribute to the protein-
flavin interaction. Such properties are unique and set the ActVB family apart 





NAD(P)H :flavin oxidoreductases or flavin reductases are enzymes 
defined by their ability to catalyze the reduction of free flavins, riboflavin, 
flavin mononucleotide (FMN) or flavin adenine dinucleotide (FAD), by 
reduced pyridine nucleotides, NADPH or NADH (1). As flavins do not bind 
tightly to them, flavin reductases should not be classified as flavoproteins. What 
the enzyme does is to provide an active site that transiently accommodates both 
the reduced pyridine nucleotide and the flavin, close to each other, in such a 
relative orientation, that the direct hydride transfer can be enormously 
accelerated (2, 3). The real biological function of the reduced flavins, the 
released products of the catalyzed reaction, is still not well understood. Free 
reduced flavins have been suggested to play an important role as redox 
mediators in iron uptake and metabolism in prokaryotes (4) or in light emission 
in bioluminescent bacteria (5, 6). More recently a group of flavin reductases has 
been found to be essential in combination with flavin-dependent oxygenases (7-
13), such as those involved in antibiotic biosynthesis, as discussed below (7-9).  
 Organisms have evolved a great variety of such enzymes, which can thus 
be classified within several families or subfamilies according to their sequence 
similarities and biochemical properties. Because of their simplicity and their 
variety, flavin reductases thus provide a unique tool to understand how a 
polypeptide chain deals with both the isoalloxazine  ring and the ribityl chain of 
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a flavin molecule to modulate its binding constant, to accelerate its reduction by 
reduced pyridine nucleotide and to use it for a diversity of functions. 
Surprisingly, our knowledge of this class of enzymes is very limited so far and 
this is the reason why flavin reductases have been the subject of intensive 
investigations in our laboratory in the recent years (3, 14-17). 
 The prototype of one group of flavin reductases is the Fre enzyme found 
in Escherichia coli (18) and also in luminescent bacteria (19). The enzyme from 
E. coli consists of a single polypeptide chain with a molecular mass of 26 kDa. 
It uses both NADPH and NADH as the electron donor and a great variety of 
flavin analogues as electron acceptors (14, 17). This clearly demonstrates that 
the recognition of the flavin by the polypeptide chain occurs exclusively 
through the isoalloxazine ring, with very limited contribution of the ribityl side 
chain (3, 14). The crystal structure of Fre (3) reveals that the general enzyme 
structure is, despite very low sequence similarities, similar to the structures of a 
large family of flavoenzymes, with spinach ferredoxin-NADP
+
 reductase (FNR) 
as the prototype (20). It provides insights to the understanding of the structural 
basis for the difference in flavin recognition between a flavoprotein and a flavin 
reductase.  
 A second group of flavin reductases, different from the Fre family and 
the flavin reductases purified from bioluminescent bacteria, has recently 
emerged (7-13). However, very few members of this group were purified to 
homogeneity and carefully characterized. These enzymes are defined on the 
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basis of their amino acid sequence similarities and their role during biological 
oxidation reactions. Indeed some monooxygenase systems depend on the 
presence of a reduced flavin, mainly FMNH2, as a co-substrate rather than a 
prosthetic group. The flavin is supposed to react with molecular oxygen in the 
active site of the monooxygenase component in order to generate a flavin 
hydroperoxide intermediate that serves as the active oxidant for substrate 
oxidation. A separate flavin reductase is thus absolutely required to supply the 
reduced flavins (with NADPH or NADH as the reductant) that diffuse to the 
oxygenase component. In the recent years the following flavin reductases have 
been shown to belong to this family: ActVB (7), SnaC (8) and VlmR (9) for the 
biosynthesis of the antibiotics actinorhodin in Streptomyces coelicolor, 
pristinamycin in Streptomyces pristinaespiralis and valanimycin in 
Streptomyces viridifaciens; HpaC (10) for the oxidation of 4-
hydroxyphenylacetate in E. coli ; DszD (11) for the conversion of sulfides to 
sulfoxides and sulfones in Rhodococcus sp. allowing the utilization of these 
microorganisms in fossil fuel desulfurization biotechnological processes;  cB 
(12) for the degradation of nitrilotriacetate in Chelatobacter heintzii . It should 
be noted that a flavin reductase called Fer (21, 22), with some homology to 
ActVB and SnaC, found as a ferric reductase in the hyperthermophilic archaea 
Archaeoglobus fulgidus, has been structurally characterized in complex with 
FMN (22).  
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Considering the biological importance of this group of flavin reductases 
and the very limited amount of available information regarding their substrate 
specificity, reaction mechanisms and three-dimensional structure, we found 
worth characterizing these enzymes in more detail in order to compare them to 
the Fre enzyme and get new insights to the general understanding of the 
protein-flavin interaction. We have chosen ActVB as a representative of this 
group of flavin reductase and report original data showing that ActVB has a 





Enzyme Assay. In the standard aerobic assay, flavin reductases activities were 
carried out under aerobic conditions allowing continuous reoxidation of reduced 
flavin by oxygen. Flavin reductase activity was determined at 25 °C from the 




) due to the 
oxidation of NADH, using a Varian Cary 1 Bio spectrophotometer. Under 
standard conditions, the spectroscopic cuvette contained, in a final volume of 
500 l, 50 mM Tris/HCl, pH 7.6, 100 µM NADH and 50 µM FMN. The 
reaction was initiated by adding 0.5-1 µg of enzyme. Enzyme activities were 
determined from the linear part of the progress curve, with less than 10% of 
reduced pyridine nucleotide utilized over the time course of the reaction. One 
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unit of activity is defined as the amount of protein catalyzing the oxidation of 1 
mol of NADH per min. When high concentrations of NAD(P)H were 
investigated, a 0.1 cm path length cuvette was used (final volume 0.3 ml). The 
hydrophobic flavin analogues lumichrome, alloxazine and lumiflavin were 
dissolved in 100 % Me2SO and the enzymatic assays thus contained 90 mM 
Me2SO, final concentration. Me2SO concentrations up to 500 mM had no 
measurable effect on Km and Vm values.  
 NAD(P) analogs and flavin concentrations were determined 
spectroscopically using the following extinction coefficients : AMP and ADP-




























.   
ActVB expression plasmids. For the production of wild-type ActVB, pACTVB 
plasmid was used (7), where actVB structural gene was placed under the control 
of the T7 polymerase promotor, in the pT7-7 plasmid. For the production of 
ActVB-His as C-terminal histidine-tagged fusion protein, the actVB gene was 
amplified by PCR from the plasmid pACTVB (7) with the oligonucleotide 
primers GGGAATTCCATATGGCTGCTGACCAGG and 
CGCGGATCCTCAATGGTGATGGTGATGGTGACCGGCATGCGCGGGCA
C, in order to introduce EcoRI, NdeI and BamHI restriction sites (underlined) 
and the 6 histidine codons (italics). The 549-base pairs PCR product was 
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digested with EcoRI-BamHI and the resulting fragment was ligated in pUC18 
(pUC18-ActVB). This plasmid was sequenced to confirm that no changes had 
been introduced during PCR amplification. The NdeI-BamHI fragment from 
pUC18-ActVB was subsequently cloned in pT7-7 resulting in the plasmid 
pACTVB his-tag. 
Preparation of soluble extracts. E. coli B834(DE3) pLysS transformed with the 
appropriate plasmid (pACTVB or pACTVB his-tag) was grown at 37°C and 
220 rpm in a 3-liter Erlenmeyer flask containing 1 liter of Luria-Bertani 
medium in the presence of 200 g/ml ampicillin and 34 g/ml 
chloramphenicol. Growth was monitored by following the absorbance at 600 
nm. Expression of ActVB and ActVB-His recombinant proteins was induced by 
adding IPTG to a final concentration of 250 M when the optical density of the 
culture was about 0.3. To minimize the formation of insoluble protein 
aggregates, cultures were cooled to 25°C after addition of IPTG and then 
further grown for 5 h. Cells were collected by centrifugation for 10 min at 
6500xg at 4°C. Extraction of soluble proteins was performed by lysozyme 
digestion and freeze-thawing cycles, in the presence of antiprotease complete 
buffer. All of the following operations were performed at 4°C. After 
ultracentrifugation at 45,000 rpm during 90 min in a Beckman 60 Ti rotor, the 
supernatant was used as soluble extracts for purification.  
Purification of ActVB. The soluble extracts (130 mg) were loaded onto an 
ACA54 column (360 ml) previously equilibrated with 10 mM Tris/HCl, pH 7.6, 
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10% glycerol, 10 mM EDTA. Proteins were eluted with a flow rate of 0.3 
ml/min. Fractions containing flavin reductase activity were pooled and 
concentrated to 2 ml using a Diaflo cell equipped with a YM 10 membrane. The 
concentrated enzyme solution was loaded onto a Superdex 75 column (120 ml 
from Pharmacia) equilibrated with 25 mM Tris/HCl pH 7.6, 10% glycerol, 10 
mM EDTA (buffer A). Proteins were eluted with the same buffer at a flow rate 
of 0.8 ml/min. Fractions containing flavin reductase activity were pooled and 
loaded onto a UNO Q column (6 ml, Bio-Rad), equilibrated with buffer A. A 
linear 0-500 mM NaCl gradient in buffer A was applied for 60 ml. ActVB was 
eluted with 100 mM NaCl. 
Purification of ActVB-His. The soluble extracts (180 mg) were loaded at 0.5 
ml/min onto a 25 ml Ni-NTA column (Qiagen) equilibrated with 50 mM 
Tris/HCl pH 7.6 (buffer B). Then, the column was washed with 100 ml of 
buffer B and elution was achieved with 100 mM imidazole in the same buffer at 
1 ml/min. The proteins were then immediately loaded onto a UNO Q column (6 
ml, Bio-Rad), and further eluted with a linear 0-500 mM NaCl gradient in 
buffer B for 60 ml, at 1 ml/min.  
Analytical determination. SDS-PAGE polyacrylamide gels (15% 
polyacrylamide) were done  according  to Laemmli (23). The gels were 
calibrated with the Pharmacia low molecular weight markers. The native 
molecular  mass of the protein was determined  with a Superdex  75 gel 
filtration column (120 ml, Pharmacia) equilibrated with 25 mM Tris/HCl, pH 
 10 
7.6 and 150 mM NaCl using a flow rate of 0.4 ml.min
-1
. Bovine serum albumin 
(66 kDa), ovalbumin (45 kDa), trypsine inhibitor (20.1 kDa) and cytochrome c 
(12.4 kDa) were used as the markers for molecular mass. The void volume was 
determined  with ferritin (450 kDa). Protein concentration was determined 
using the Bio-Rad protein assay reagent (24) with bovine serum albumin as a 
standard. Anaerobic experiments were carried out in a Jacomex glove box 
equipped with an HP 8453 diode array spectrophotometer coupled to the 
measurement cell by optical fibers (Photonetics system). 
Cofactor analysis. A sample of pure ActVB or ActVB-His  protein was boiled 
for 10 min in the dark, chilled on ice and then centrifuged for 10 min at 
10,000xg in order to pellet the denatured protein. An aliquot of the supernatant 
was analyzed both by UV-visible spectroscopy and by thin-layer 
chromatography on silica gel 60 F254 (Merck) with butanol-1/acetic acid/water 
(10/5/5) as the eluant. As a control, pure FMN, FAD and riboflavin were run 
separately or as a mixture, under the same conditions. 
Kinetic analysis.  The molar concentration of ActVB was calculated assuming a 
molecular weight value of the polypeptide chain of 18,260 Da (7). Reciprocal 
initial velocities (1/vi) were plotted against reciprocal substrate concentrations 
(1/[S]) and fitted with a straight line determined by a linear regression program. 
In some cases, kinetic parameters (Vm, Km, Kmapp) were determined from 
saturation curves, fitted with the equation: vi=(Vm[S])/(Km+[S]), using a 
Levenberg-Marquardt algorithm. Inhibition constants (Ki) for competitive 
 11 
inhibitors were determined using a secondary plot of the slopes from the double 
reciprocal plots against the concentration of the inhibitor [I], corresponding to 
the equation: y = (Km/Vm)(1+([I]/Ki)) (25). In the cases of noncompetitive and 
uncompetitive inhibitors, the inhibition constant (Ki) was determined using a 
secondary plot of the intercepts from the double reciprocal plot against the 
concentration of the inhibitor [I], corresponding to the equation: y = (([I]/(Ki 





Purification of ActVB 
In a first set of experiments, ActVB was overexpressed in E.coli using the 
pACTVB plasmid (7). Using the purification procedure described in the 
experimental section, a low yield (6-7 %) of purified ActVB could be obtained 
(Table I, A). This was then explained by the great instability of the flavin 
reductase activity in the soluble extracts. The activity, routinely assayed from 
the oxidation of NADH by an excess of FMN monitored 
spectrophotometrically, was found to decrease by 50 % when the protein was 
left in buffer for 3 hours at 4 °C. Addition of 10% glycerol, 10 mM EDTA and 
TM
complete buffer solution to the soluble extracts provided a significant 
stabilization of the activity (data not shown). However, even under these 
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conditions, more than 90 % of the flavin reductase activity was lost during the 
first two chromatographic steps (Table I, A). After the UNO Q column, activity 
remained stable, suggesting that instability of ActVB activity in soluble extracts 
arose from reactions with some cellular components. SDS-PAGE analysis after 
the UNO Q purification step revealed the presence of two polypeptide bands at 
18,000 and 17,000 Da (data not shown), with the same AADQGMLRDA N-
terminal sequence corresponding to the ActVB protein (7). This suggested a 
partial C-terminal proteolysis of ActVB when expressed in E. coli, as described 
previously (7). In contrast, overexpression of ActVB as a C-terminal his-tagged 
fusion protein (ActVB-His) allowed a more efficient purification of the enzyme 
(Table I, B). SDS-PAGE analysis after the UNO Q column revealed the 
presence of only one polypeptide chain at 18,000, without evidence for partial 
proteolysis (data not shown).  
Gel-filtration experiments on Superdex 75 column with ActVB and 
ActVB-His gave an apparent molecular mass  of 36,000 Da for both proteins, 
confirming the homodimeric structure for ActVB (7). 
Flavin reductase specific activities of both ActVB and ActVB-His 
proteins were found to be comparable (Table I), indicating that the C-terminal 
part of the protein lost during proteolysis was not important for activity and that 
the presence of the His-tag was neutral with regard to the enzyme activity. 
However, it should be noted that from one preparation to another, we obtained 
purified proteins with slightly different specific flavin reductase activities.  
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In the following experiments presented here, we report data obtained with 
ActVB. In the case of the kinetic experiments, the same enzyme preparation 
was used allowing a direct comparison of the parameters obtained under 
different kinetic conditions. 
 
Flavin content of ActVB  
Purified ActVB was yellow, with absorption spectra typical for a flavin-
containing protein, with maxima at 378 and 455 nm (Fig. 1). After denaturation 
of the protein by boiling for 10 min and centrifugation, the chromophore 
contained in the supernatant was analyzed by thin-layer chromatography, with 
FMN, riboflavin and FAD as standards. The chromophore was identified as 
FMN (data not shown). Quantification of the free FMN released in the 
supernatant by UV-visible spectroscopy demonstrated that the amount of FMN 
in purified ActVB varied from one preparation to another from 0.1 to 0.6 mol of 





at 455 nm for the bound FMN was calculated. 
Reconstitution experiments of ActVB with FMN or riboflavin gave the 
following results. A preparation of ActVB (50 M) containing little FMN (0.1 
mol FMN per mol of protein) was incubated with 1 mM FMN or 400 µM 
riboflavin for 1 hour in 50 mM Tris/HCl buffer pH 7.6 and then 
chromatographied on a NAP10™ column (Pharmacia) in order to remove 
unbound flavin. The protein was then analyzed both by UV-visible 
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spectroscopy and thin-layer chromatography, as previously described, in order 
to identify and quantify the bound flavin in the reconstituted ActVB. 
Reconstitution with FMN resulted in a 6-7-fold increase of the amount of 
protein-bound FMN and a protein containing 0.6 to 0.7 mol FMN per mol of 
protein (data not shown). In contrast, reconstitution with riboflavin failed to 
increase the amount of protein bound flavin and did not result in the removal of 
FMN initially bound to ActVB (data not shown).  
 
Titration of the ActVB FMN bound by NADH 
In order to verify that the FMN bound to the isolated ActVB protein was 
correctly located at the flavin reductase active site, reductive titration of FMN 
was carried out with NADH, under anaerobic conditions. A preparation of 
ActVB containing 0.5 mol of FMN per mol of ActVB polypeptide chain 
(18,260 Da) was used for that experiment. As shown in Fig. 2, addition of 
NADH caused a decrease in the absorbance at 455 nm, reflecting a reduction of 
FMN. An isosbestic point at 510 nm was observed for substoichiometric  
concentrations of NADH. In the inset of Fig. 2, a plot of the fractional 
absorbance changes at 445 nm as a function of [NADH]/[FMN] ratio showed 
that 1 mole of NADH was sufficient to reduce 1 mol of bound FMN. In 
addition, during the NADH titration, a broad absorption band above 550 nm 
developed (Fig. 2). Such a band is tentatively assigned to a charge-transfer 
complex of reduced FMN with NAD
+
 within the active site of ActVB rather 
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than to a flavin neutral semiquinone species  (26, 27), as confirmed by the 
following experiment (Fig. 3). An anaerobic solution of ActVB, containing 0.5  
mol of bound FMN per mol of polypeptide chain, EDTA and catalytic amount 
of deazaflavin was photoreduced and then titrated with increasing amounts of 
NAD
+
. As shown in Fig. 3, irradiation resulted in the decrease of the 
absorbance at 455 nm, consistent with reduction of FMN by photoreduced 
deazaflavin. When NAD
+
 was added, a broad band developed at wavelengths 
greater than 520 nm, which was similar to that observed during reaction of 
ActVB-bound FMN with NADH. In addition, no significant increase in 
absorbance at 340 nm was observed, indicating that no NADH was formed 
during incubation of reduced FMN with NAD
+
. This shows that the reduction 
of FMN by NADH at the active site of ActVB is irreversible.  
 
Flavin reductase activity is not dependent on the bound FMN 
The previous experiments have shown that the purified protein contains 
various amounts of FMN bound at its active site, depending on the enzyme 
preparation. In order to investigate the dependence of the flavin reductase 
activity of ActVB on the amount of protein-bound FMN, different preparations 
containing various amounts of FMN were assayed either with FMN or 
riboflavin as a substrate and with NADH as the electron donor (Table II). In the 
absence of exogenous flavins, only a very weak activity could be detected (data 
not shown), excluding a NADH oxidase function for ActVB. With either FMN 
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or riboflavin as a substrate, the flavin reductase activity of ActVB was found to 
be independent on the FMN content of the polypeptide chain (Table II). Since 
riboflavin does not bind to ActVB (see above), reconstitution for a flavin site 
during the enzymatic test is excluded. These observations thus rule out the 
possibility that the protein-bound FMN was involved in the flavin reductase 
activity and are consistent with ActVB being a flavin reductase accepting both 
FMN and riboflavin as substrates. It is likely that, under the assay conditions, 
the protein-bound FMN can be displaced by the large excess  of riboflavin.  
 
Kinetic analysis of ActVB 
 The dependence of the reaction catalyzed by ActVB on the concentration 
of both substrates, flavin and reduced pyridine nucleotide, was investigated by 
kinetic experiments under steady-state conditions. For all the following kinetic 
experiments, the same homogeneous enzyme preparation was used.  For such a 
bisubstrate-biproduct reaction, kinetic analysis provides insights into the 
mechanism. Double reciprocal plots of initial velocities versus substrate 
concentrations show intersecting patterns in the case of a sequential mechanism 
and parallel patterns for a ping-pong mechanism (25). Flavin reductase activity 
was determined as a function of NADH concentration at several levels of FMN 
(Fig. 4A) and as a function of FMN concentration at several levels of NADH 
(Fig. 4B). Initial velocities followed typical Michaelis-Menten kinetics since 
double reciprocal plots of the data showed a series of lines. Moreover, a ping-
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pong mechanism could be excluded since the lines were intersecting each other 
at the same point at the left of the vertical axis. A sequential mechanism for 
ActVB is thus indicated (25). However whether it is an ordered or a random 
sequential mechanism cannot be concluded from such an experiment. It may be 
experimentally deduced from the inhibition studies described below (28). 
 When the enzyme activity was determined as a function of NADH 
concentration in the absence or in the presence of three concentrations of 
adenosine 5'-monophosphate (AMP, Scheme 1), a dead-end inhibitor, double 
reciprocal plots revealed typical competitive inhibition kinetics (Fig. 5A). A Ki 
value of 3 ±0.5 mM was obtained for AMP. On the other hand, a pattern of non-
competitive inhibition was observed for AMP with respect to the FMN 
substrate, with a Ki value of 7.7 ±0.4 mM 
1
 (Fig. 5B). Furthermore, 
lumichrome, a flavin analogue (Scheme 1) with no redox activity, was a 
competitive inhibitor with respect to FMN with a Ki value of 104 ±17 µM (Fig. 
6A) and an uncompetitive inhibitor with respect to NADH, with a Ki value of 
91 ±1 µM (Fig. 6B). All these data support the conclusion that the flavin 
reductase has an ordered mechanism with NADH binding first and FMN being 
the second substrate  (28).  
 The kinetic mechanism of product release has been determined by 
studying inhibition by products (25). When NADH concentration was varied 
                                                 
1
 For a two-substrate enzyme, the Ki values for an inhibitor with respect to each substrate 
should not be necessary equal (25).   
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with a fixed concentration of FMN, inhibition by NAD
+
 was found to be non-
competitive with respect to NADH (data not shown). When FMN was varied at 
a fixed NADH concentration, NAD
+ appeared to inhibit non competitively (data 
not shown). This now suggests that the first product to be released is NAD
+
, 
followed by the reduced flavin. 
 
Flavin substrate specificity  
 Scheme 1 shows the structures of the various flavin analogs used as 
substrates or inhibitors. Table III reports the kinetic parameters for each 
substrate obtained during enzymatic reduction by NADH under steady-state 
conditions. The apparent Km  values were determined in experiments where 
flavin reductase activities were measured as a function of the concentration of a 
given substrate in the presence of saturating concentrations of the other 
substrate. In addition, the Km and kcat values for the FMN substrate were 
determined from the data shown in Figures 4A and 4B, using the Dalziel 
treatment which is well adapted for a sequential bireactant mechanism (29, 16-
17). The latter were found to be 0.78 ±0.10 M and 8.9 ±0.3 s-1 respectively, 
which are comparable to those reported in Table III.  
 As shown in Table III, Vmax values (reported as kcat values) were only 
slightly sensitive to modifications of the flavin moiety both at the isoalloxazine 
ring and the ribityl side chain. On the contrary, Km values for the flavin 
substrate strongly depended on the nature of the substituent at the N-10 position 
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of the isoalloxazine ring. As previously reported in (7), FMN was found to be 
the best substrate, with a Km value of 1 µM. Riboflavin and FAD exhibited a 8-
fold larger Km value, suggesting that the terminal phosphate group on the ribityl 
chain of the FMN molecule provided significant stabilization of the flavin-
protein complex.   Lumiflavin, with a methyl group at N-10 position, was also a 
substrate of ActVB, although its Km value was much larger than that for FMN, 
FAD or riboflavin. This shows the importance of the isoalloxazine ring for the 
flavin-protein recognition, in agreement with lumichrome and alloxazine being 
competitive inhibitors of FMN, with Ki values of 104 and 93 µM, respectively 
(Fig. 6A and Table III).  
 In the case of a sequential ordered mechanism, the Kd value for a 
competitive inhibitor with respect to the second substrate can be calculated 
from its Ki value according to the following equation : Kd = Ki /(1 + Kd 
NADH/[NADH]) (30), where Kd NADH is the dissociation constant for the first 
substrate NADH and [NADH] the concentration of NADH used to determine 
the Ki value. Using     Kd NADH = 7.8 ±0.7 µM (see below), Kd values for 
lumichrome and alloxazine  of 87 ±14 and 78 ±18 µM, respectively, could be 
obtained.  The Kd value for lumichrome value is comparable to the Km value for 
lumiflavin (69 ±8 µM), its closest flavin substrate analogue. This suggests that 
Km values for the flavin substrates represent good approximations for the 
corresponding Kd values during catalysis.  
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 The role of the ribityl chain in the flavin-protein interaction was further 
investigated with flavin analogs carrying different substituents at the N-10 
position (Scheme 1 and Table III). Since binding of the flavin molecule seems 
to involve the ribityl-phosphate chain as well, we have examined the role of the 
OH ribityl groups in that recognition (Table III). Km values for flavins were in 
that other: 1 < riboflavin < 3 < 2 < lumiflavin. Furthermore, in the case of 
compound 2, the kcat value was significantly decreased with regard to kcat values 
with 3 and riboflavin. Those data suggest that the 2'-OH contributes to the 
protein-flavin recognition, whereas the 3'-OH plays a minor role. It should be 
noted that ribitol, up to 10 mM, is not an inhibitor (data not shown). 
 
Reduced pyridine nucleotide substrate specificity 
 Table IV shows the kinetic and thermodynamic parameters for various 
NAD(P)H analogs (Scheme 1) obtained during enzyme reaction under steady-
state conditions. The Km value for the NADH substrate was also determined 
from the data shown in Figures 4A and 4B, using the Dalziel treatment (29, 16-
17), and found to be 9.7±0.4 M, which is comparable to the value reported in 
Table IV. As previously reported in (7), ActVB is strictly specific for NADH. 
NADPH cannot be used as a substrate, even at very high concentrations (up to 
0.8 mM). The Km value for NADH (6.6 ± 0.5 M, Table IV) was comparable to 
its Kd value (7.8 ± 0.7 M) determined from the Dalziel mathematical treatment 
of the initial velocities data reported in Fig. 4A and 4B (29, 16-17). Ki values 
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for AMP and ADP-ribose, which are competitive inhibitors with respect to 
NADH (Fig 5A and not shown, respectively), were very large (3 and 17.4 mM, 
respectively, Table IV). In the case of a sequential ordered mechanism, the 
inhibition constant Ki for a competitive inhibitor with respect to the first 
substrate is equal to the dissociation constant of the enzyme-inhibitor complex 
(30). Comparison of the Ki values for AMP and ADP-ribose with the Kd value 
for NADH thus indicates that the nicotinamide ring plays a major role in the 
binding of NADH molecule to ActVB. On the other hand, NMNH, the NADH 
analog lacking the AMP part of the molecule (Scheme 1), was neither a 
substrate nor an inhibitor, up to a concentration of 1 mM (Table IV). This now 
indicates that the nicotinamide ribose phosphate part of the NADH is not 
recognized by itself either. Taken together, these data suggest that the NADH 
molecule is recognized by ActVB as a whole and that individual contributions 
of the different parts of the molecule cannot provide enough interactions unless 








The enzyme named Fre can be considered as a prototype of a whole class 
of flavin reductases, the enzymes catalyzing the reduction of riboflavin, FMN 
and FAD by NADPH and NADH (14). This is the most extensively 
characterized flavin reductase so far (2, 3, 14, 16-18). Kinetic analysis and 
structural characterization in our laboratory have shown that this enzyme binds 
the flavin, with a preference for riboflavin, almost exclusively through 
interactions with the isoalloxazine ring (14) and reduced pyridine nucleotides, 
preferably NADPH, mainly through interactions with the nicotinamide moiety 
(17). These are unique binding modes. The enzyme proceeds by a sequential 
ordered mechanism, binding the NADPH first and providing a site that 
accommodates both substrates in a ternary complex from which the optimized 
hydride transfer occurs (2, 14). 
ActVB belongs to a different and much less well-characterized group of 
flavin reductases. These enzymes are generally associated to flavin-dependent 
monooxygenases and have no sequence homology with the Fre family (7-13). 
Here we report a detailed study of ActVB that allows comparison to Fre. As 
discussed below we show that ActVB is different from Fre also with respect to 
substrate specificities and recognition. 
The first question we have addressed is whether ActVB is a flavoprotein 
or not. Previous reports had not provided a clear answer to that question and 
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furthermore in our hands preparations of ActVB had highly variable amounts of 
protein-bound FMN. Furthermore, whereas some members of the ActVB family, 
such as HpaC (10), were isolated without bound cofactors others, such as SnaC 
(8), were shown to contain significant amounts of flavin bound to the 
polypeptide chain after purification. The presence of FMN in ActVB could be 
explained either by a tight interaction between ActVB and FMN allowing 
isolation of the flavin reductase with its substrate or by a loss of a prosthetic 
FMN group from a flavoprotein during purification. It should be noted that some 
flavoproteins, such as sulfite reductase, may display some flavin reductase 
activity (15). However in this case, the internal flavin cofactor mediates an 
unspecific electron transfer from NAD(P)H to the exogenous flavin substrate as 
well as other acceptors (quinones, ferric iron, cytochrome c…) and thus 
proceeds through a ping-pong mechanism (15). 
The results presented here unambiguously demonstrate that ActVB is not 
a flavoprotein but a flavin reductase displaying a low Kd value for FMN. First, 
with all substrates, FMN, riboflavin and FAD, the kinetic data nicely fit with a 
sequential and not with a ping-pong mechanism (Fig. 4). Second, FMN and 
riboflavin reductase activities do not depend on the amount of FMN bound to 
the protein used for the assay (Table II). Third, ActVB cannot bind more than 
one equivalent of FMN as shown by reconstitution experiments, in agreement 
with the presence of only one FMN binding site. Furthermore, this site is 
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directly accessible to NADH where electron transfer can occur as shown from 
the formation of a charge transfer complex (Fig.2).  
Kinetic analysis of ActVB with a variety of flavin and NAD(P)H analogs 
allows the first detailed understanding of the protein-substrate interaction with 
this class of flavin reductases. Clearly the isoalloxazine ring provides a major 
site of interaction with the polypeptide chain. Lumiflavin, lacking a lateral 
chain, is a substrate and lumichrome and alloxazine  are competitive inhibitors 
with respect to FMN, with  Kd values comparable to the Km value for lumiflavin 
(70-80 µM). In addition, the fact that Kd values for lumichrome and alloxazine 
are comparable shows that the methyl groups of the isoalloxazine ring at 
positions 7 and 8 are not important for the protein-flavin interaction. On the 
other hand, the Km values for the natural substrates, riboflavin and FMN, are 
much lower (8 and 1 µM, Table III). Thus the ribityl chain also contributes to 
the binding. The catalytic efficiency of the enzyme with compound 1 and with 
FMN as substrates suggest that the 2’-OH of the sugar chain and the phosphate 
group play significant roles in the interaction of the substrate with the 
polypeptide chain.  FMN is the better substrate in agreement with the finding 
that the purified preparations of ActVB contained FMN exclusively. This 
property represents a clear difference between the ActVB and the Fre flavin 
reductase families. Indeed, in the case of Fre, the recognition of the flavins 
occurs almost exclusively at the level of the isoalloxazine ring, with Km values 
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for riboflavin and FMN comparable to that for lumiflavin and to the Kd value for 
the inhibitor lumichrome, in the 0.5-2 µM range (14).  
The first and only available structural information on the ActVB family 
comes from the three dimensional structure of the Fer protein, from 
Archaeoglobus fulgidus, in complex with the FMN substrate (22). Since ActVB 
displays significant sequence homology with Fer (22% identity and 34% 
similarity, data not shown), it should be possible to identify some key residues 
for flavin binding in ActVB. However, this approach proved to  be rather limited 
since the great majority of the residues involved in FMN binding in the Fer 
structure are not conserved in sequences of Fer homologs and many of these 
residues interact with FMN through main chain N and O atoms (22). 
Nevertheless, it is likely that ActVB should display structural similarities with 
Fer, with a FMN binding site that provides hydrogen bonds, ion pair interactions 
and electrostatic dipole interactions to the various parts of the substrate, the 
isoalloxazine ring, the OH groups of the ribitol chain and the phosphate group. 
In contrast, the structure of Fre, in complex with riboflavin, shows interactions 
of the polypeptide chain mainly with the isoalloxazine ring. All these results are 
consistent with the kinetic analysis reported here. 
As far as the binding of reduced pyridine nucleotides is concerned, again 
large differences between the ActVB and the Fre families are observed. Whereas 
Fre recognizes NAD(P)H mainly through the nicotinamide ring, allowing 
NMNH to be a good substrate (17), ActVB interacts with the various parts of the 
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molecule. This is shown from the drastic increase of the Kd value for both 
inhibitors AMP and ADP-ribose and from the observation that NMNH is neither 
an inhibitor nor  a substrate. It is also remarkable that ActVB is highly specific 
for NADH whereas Fre can use both NADH and NADPH. Again we learn very 
little from the structure of the homolog, the Fer protein from A. fulgidus, since 
the residues interacting with NADP
+
, in a crystal of the Fer-FMN complex 
soaked with NADP
+
, are not conserved in ActVB (22). However, as illustrated 
by the characterization of a strong charge-transfer complex between reduced 
flavin and NAD
+
 in the active site of ActVB (Fig. 2 and 3), it is likely that, as in 
Fer, the nicotinamide ring of the pyridine nucleotide in ActVB packs against the 
isoalloxazine ring of the flavin, with the C4 atom of nicotinamide and the N5 
atom of the flavin at a few Å from each other in a stacking arrangement typical 
for direct hydride transfer in flavoproteins. A specific structural analysis of 
ActVB is required to better understand the various aspects of substrate 
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Figure 1. Absorption spectra of the purified ActVB (60 µM in Tris/HCl 50 mM 
pH 7.6). 
 
Figure 2. Anaerobic reduction of ActVB (130µM) containing FMN-bound 
(65µM) by NADH, in 50mM Tris/HCl buffer pH 7.6. Are shown, from top to 
the bottom at 455 nm, the spectra recorded after addition of a 0 ( ), 0.2, 0.4, 
0.6, 0.8, 1, 1.1, and 1.3 ( ) -fold molar excess of NADH with respect to FMN. 
In the inset is shown a plot of fractional absorbance changes observed at 455 
nm, as a function of the [NADH]/[FMN] ratio. 
 
Figure 3. Anaerobic titration of reduced ActVB-bound FMN with NAD
+
. () 
Spectra of ActVB (130µM) containing oxidized FMN-bound (65µM) in 50mM 
Tris/HCl buffer pH 7.6, 5 mM EDTA and 1.4 µM 5-deazaflavin. () After 
irradiation for 30 min.  After irradiation and anaerobic addition of 5 M (), 20 
M () and 70 M ( ) NAD+. 
 
Figure 4. A, flavin reductase initial velocity vi as a function of NADH 
concentration in the presence  of 11 (), 3.3 (), 2.2 (), 1.1 (), 0.6 ( ) or 
0.22 µM () FMN. B, flavin reductase initial velocity vi as a function of FMN 
concentration in the presence of 11 (), 8.2 (), 6.6 (), 4 (), 2 ( ) or 1.3 
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µM () NADH. The flavin reductase concentration e used in these assays was 
0.0545 µM. The results are presented in the form of double reciprocal plots. 
 
Figure 5. A, AMP as a competitive inhibitor for NADH. The enzyme initial 
velocity vi was assayed as a function of NADH concentrations using 7 µM FMN 
in the absence () or in the presence of 2 (), 5 () or 7 mM () AMP. In the 
inset is shown a secondary plot of the slopes derived from Fig. 5A against 
[AMP], fitted with a straight line corresponding to the equation: y = (Km/Vm) 
(1+([I]/Ki)). B, AMP as a noncompetitive inhibitor for FMN. The enzyme initial 
velocity vi was assayed as a function of FMN concentrations using 40 µM 
NADH in the absence () or in the presence of 2 (), 5 () or 7 mM () AMP. 
In the inset is shown a secondary plot of the intercepts derived from Fig. 5B 
against [AMP], fitted with a straight line corresponding to the equation: y = 
(([I]/(Ki Vm)) + 1/Vm. The flavin reductase concentration e used in these assays 
was 0.0545 µM. The results are presented in the form of double reciprocal plots. 
 
Figure 6. A, lumichrome as a competitive inhibitor for FMN. The enzyme initial 
velocity vi was assayed as a function of FMN concentrations using 40 µM 
NADH in the absence () or in the presence of 50 (), 100 (), 150 (), 200 
( ) or 260 µM () lumichrome. In the inset is shown a secondary plot of the 
slopes derived from Fig. 6A against [lumichrome], fitted with a straight line and 
corresponding to the equation: y = (Km/Vm) (1+([I]/Ki)). B, lumichrome as an 
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uncompetitive inhibitor for NADH. The enzyme initial velocity vi was assayed 
as a function of NADH concentrations using 7 µM FMN in the absence () or 
in the presence of 50 (), 100 (), 150 (), 200 ( ) or 260 µM ()  
lumichrome. In the inset is shown a secondary plot of the intercepts derived 
from Fig. 6B against [lumichrome], fitted with a straight line corresponding to 
the equation: y = (([I]/(Ki Vm)) + 1/Vm. The flavin reductase concentration e used 
in these assays was 0.0545 µM. 
 














(mol min-1 mg-1) 
Recovery 
(%) 
Soluble fraction 130 910 7 100 
ACA 54 40 360 9 40 
Superdex 75 3.6 61 17 6.7 
UNO Q 1.8 57 32 6.2 
 
 









(mol min-1 mg-1) 
Recovery 
(%) 
Soluble fraction 180 900 5 100 
Ni-NTA 11 308 28 34 
UNO Q 8 280 35 31 
 
a
 Enzyme activity was determined at 25 °C using the standard aerobic assay  




Flavin reductase activity of different ActVB preparations, containing various 
amounts of bound FMN, measured in the presence of NADH (200 M) and 
FMN (100 M) or riboflavin (100 M) as substrates, in 50 mM Tris/HCl pH 
7.6. 
 
Protein bound FMN 
(mol FMN/mol ActVB) 






 FMN Riboflavin 
0.1 42 42 
0.3 39 45 
0.5 40 39 























Riboflavin Substrate 8.1±0.9 13±0.6 - - 
FMN Substrate 1.0±0.1 9.2±0.4 - - 
FAD Substrate 8.7±0.6 8.2±0.7 - - 
Lumiflavin Substrate 69±8 9.9±0.3 - - 
1 Substrate 3.7±0.4 8.1±0.2 - - 
2 Substrate 15.7±2.5 3.6±0.1 - - 


















 The enzyme preparation  used in these experiments exhibited a slightly smaller 
specific activity than that used in the experiments reported in Table II.  
b
 The concentration of NADH used for the determination of Km and kcat values 
was 200 µM. 
c
 From the data of Fig. 6A. 
d
 Experimental conditions as in Fig. 6A, except for alloxazine concentrations (0, 




Apparent kinetic and thermodynamic constants for NADH derivates  
with FMN as electron acceptor. 







NADH Substrate 6.6±0.5 7.8±0.7 
AMP 
b
 Inhibitor competitive/NADH - 3000±500 
ADP-ribose 
c
 Inhibitor competitive/NADH - 17400±4000 
NADPH Not a substrate up to 0.8 mM - - 
 
NMNH 
Not a substrate up to 1 mM 




 The concentration of FMN used for the determination of the Km and kcat values 




 From the data of Fig. 5A. 
c
 Experimental conditions as in Fig. 5A, except for ADP-ribose concentrations 
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